PARIS, Dec 24 (APM) - France's new social security funding law (LFSS) for 2015 was published in the Official Journal (JO) on Wednesday and comprises 93 articles.
The articles specifically concerning the health care system are briefly presented below:
Article 1: regulatory mechanism applicable to drugs to treat chronic hepatitis C
Article 14: overhaul of the safeguard clause relating to drugs (the “k rate” becomes the “L rate”)
Article 57: extension of the mechanism for speedier reimbursement approval to innovative procedures
Article 61: extension of the generics’ repertoire to drugs whose active substance is of plant or mineral origin
Article 62: integration of drugs dispensed for administration by inhalation within the generics’ repertoire
Article 63: reduction in the national tariff where applying to products on the 'liste en sus' (a list of costly hospital-use products) whose prescription level is judged too high
Article 64: incentive to prescribe generic drugs in hospitals
Article 66: for products that hospital pharmacists can dispense to out-patients, hospitals are sometimes able to purchase the products at prices below the reference price and so far have been able to keep this difference, but they are now to share the difference with health insurance
Article 67: speedier setting of reference prices for drugs featuring in the 'liste en sus'
mh/aki/hlc
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
